Inspira Technologies Explores Artificial Womb Use for ART100 Device

Ticker: IINNW · Form: 6-K · Filed: Apr 3, 2024 · CIK: 1837493

Inspira Technologies Oxy B.H.N. LTD 6-K Filing Summary
FieldDetail
CompanyInspira Technologies Oxy B.H.N. LTD (IINNW)
Form Type6-K
Filed DateApr 3, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: medical-device, research-and-development, new-application

TL;DR

Inspira exploring ART100 for artificial womb tech - big potential if it works.

AI Summary

On April 3, 2024, Inspira Technologies Oxy B.H.N. Ltd. announced a program to explore the use of its INSPIRA ART100 device for an artificial womb. This initiative aims to pioneer the applicable use of the device in this novel application.

Why It Matters

This development could represent a significant advancement in reproductive technology and fetal development research if successful.

Risk Assessment

Risk Level: medium — The success of pioneering a new application like an artificial womb is inherently uncertain and carries significant research and development risks.

Key Players & Entities

FAQ

What is the specific goal of the program announced by Inspira Technologies?

The program aims to pioneer the applicable use of the INSPIRA ART100 device for an artificial womb.

When was this program announced?

The program was announced on April 3, 2024.

What is the name of the device Inspira Technologies is focusing on?

The device is named INSPIRA ART100.

What type of filing is this report?

This is a Form 6-K report of foreign private issuer.

What is the company's principal executive office address?

The address is 2 Ha-Tidhar St. Ra'anana 4366504, Israel.

Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 8.7 · Accepted 2024-04-03 08:56:49

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: April 3, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing